URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - UroGen Pharma Ltd. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding its lead product UGN-102 and its clinical study design [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Cockrell v. UroGen Pharma Ltd., and it includes purchasers of UroGen securities from July 27, 2023, to May 15, 2025 [1]. - Investors have until July 28, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that UroGen's clinical study for UGN-102 was inadequately designed, lacking a concurrent control arm, which undermined the evidence of its effectiveness [3]. Group 2: Allegations Against UroGen - The lawsuit alleges that UroGen ignored FDA warnings regarding the study design for UGN-102, which could jeopardize the approval of its New Drug Application (NDA) [3][4]. - Following the FDA's briefing document on May 16, 2025, which criticized the study design, UroGen's stock price fell nearly 26% [4]. - On May 21, 2025, the Oncologic Drugs Advisory Committee voted against the approval of UGN-102, leading to a further decline of nearly 45% in UroGen's stock price [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased UroGen securities during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [7].